News

PNAS1d
HARC as an open-shell strategy to bypass oxidative addition in Ullmann–Goldberg couplings
Contributed by David W. C. MacMillan, July 8, 2020 (sent for review June 11, 2020; reviewed by Scott J. Miller and F. Dean Toste) ...
Targeted Oncology2d
177Lu PSMA-617 Improves rPFS in mHSPC: PSMAddition Trial
The PSMAddition trial shows 177Lu PSMA-617 significantly delays progression in mHSPC when added to hormone therapy, with a ...
Clinical Trials Arena4d
Novartis reports topline outcomes from trial of Pluvicto for prostate cancer
Novartis has reported topline outcomes from the Phase III PSMAddition trial’s pre-specified interim analysis of Pluvicto.
Pharmabiz4d
Novartis Pluvicto demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive mHSPC
Novartis Pluvicto demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive mHSPC: Basel Tuesday, June 3, 2025, 12:00 Hrs [IST] ...
Novartis’ Pluvicto Shows Promise in Early Stage Prostate Cancer
Novartis (NYSE:NVS) announced positive topline results from the Phase III PSMAddition trial, which showed that its targeted ...
Clinical trial shows strong results for Novartis’ cancer drug
Investing.com -- Novartis (SIX: NOVN) on Monday said that its cancer drug Pluvicto showed positive results in a late-stage ...
Novartis Says Phase III PSMAddition Trial Met Its Primary Endpoint
Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...